AlphaCrest Capital Management’s Charles River Laboratories CRL Stock Holding History

AlphaCrest Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,388	Closed	-$273K	–	268
2022 Q3	$273K	Buy	1,388 +416	+43%	+$89.8K	0.02%	1168
2022 Q2	$208K	Sell	972 -1,642	-63%	-$401K	0.01%	1203
2022 Q1	$742K	Sell	2,614 -1,757	-40%	-$542K	0.04%	695
2021 Q4	$1.65M	Buy	4,371 +3,240	+286%	+$1.26M	0.06%	545
2021 Q3	$467K	Buy	+1,131	New	+$470K	0.02%	943
2020 Q3	–	Sell	-1,213	Closed	-$211K	–	1104
2020 Q2	$211K	Sell	1,213 -3,192	-72%	-$509K	0.04%	820
2020 Q1	$556K	Buy	4,405 +778	+21%	+$117K	0.07%	514
2019 Q4	$554K	Buy	+3,627	New	+$502K	0.05%	723
2019 Q1	–	Sell	-5,400	Closed	-$611K	–	837
2018 Q4	$611K	Buy	+5,400	New	+$676K	0.18%	176

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AlphaCrest Capital Management's CRL Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Charles River Laboratories (CRL) in Q4 2022, closing a stake of 1,388 shares — an estimated $273K sold.

AlphaCrest Capital Management first reported a position in CRL in Q4 2018 and held it in 9 quarters. The position peaked at $1.65M in Q4 2021. 628 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

AlphaCrest Capital Management reported no remaining Charles River Laboratories position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 1,388 Charles River Laboratories shares in Q4 2022, an estimated $273K.
AlphaCrest Capital Management first reported a position in Charles River Laboratories in Q4 2018 and held it in 9 quarters.
AlphaCrest Capital Management's Charles River Laboratories position peaked at $1.65M in Q4 2021.
628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.